Eisai Co., Ltd. Logo

Eisai Co., Ltd.

A global, research-based pharmaceutical firm that develops and markets prescription and OTC drugs.

4523 | T

Overview

Corporate Details

ISIN(s):
N/A
LEI:
Country:
Japan
Address:
文京区小石川4丁目6番10号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Eisai Co., Ltd. is a global, research-based pharmaceutical company founded in 1941. It is engaged in the discovery, development, manufacturing, and marketing of pharmaceutical products, with a portfolio that includes prescription medicines and over-the-counter drugs. The company operates under its core "human health care" (hhc) philosophy, which prioritizes patients and their families to enhance the benefits provided by healthcare. A key corporate initiative involves improving access to medicines for people in developing and emerging countries, exemplified by its program to supply treatments for lymphatic filariasis.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-04 07:00
Regulatory News Service
訂正報告書(大量保有報告書・変更報告書)
Japanese 46.9 KB
2025-06-19 09:25
Post-Annual General Meeting Information
臨時報告書
Japanese 31.9 KB
2025-06-13 04:30
Governance Information
内部統制報告書-第113期(2024/04/01-2025/03/31)
Japanese 25.1 KB
2025-06-13 04:29
Registration Form
確認書
Japanese 8.1 KB
2025-06-13 04:28
Annual Report
有価証券報告書-第113期(2024/04/01-2025/03/31)
Japanese 5.2 MB
2025-06-03 08:00
Major Shareholding Notification
変更報告書
Japanese 39.0 KB
2025-05-13 08:00
Major Shareholding Notification
大量保有報告書
Japanese 37.9 KB
2025-05-08 09:00
Regulatory News Service
公開買付報告書
Japanese 41.0 KB
2025-04-01 08:00
M&A Activity
訂正公開買付届出書
Japanese 177.2 KB
2025-03-17 06:00
M&A Activity
公開買付届出書
Japanese 348.4 KB
2025-03-12 07:06
Board/Management Information
臨時報告書
Japanese 21.8 KB
2024-12-11 02:14
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 23.2 KB
2024-11-15 02:00
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 21.7 KB
2024-11-08 06:17
Regulatory News Service
確認書
Japanese 8.0 KB
2024-11-08 06:16
Interim Report
半期報告書-第113期(2024/04/01-2025/03/31)
Japanese 268.5 KB

Automate Your Workflow. Get a real-time feed of all Eisai Co., Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Eisai Co., Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
bioMérieux Logo
Provides in vitro diagnostic solutions for clinical and industrial microbiology.
France BIM
BioPorto Logo
IVD company developing NGAL biomarkers for early acute kidney injury (AKI) risk assessment.
Denmark BIOPOR
Biosergen AB Logo
Developing novel antifungal drugs for life-threatening infections in immunocompromised patients.
Sweden BIOSGN
Bio Solution Co.,Ltd. Logo
Develops cell therapies for degenerative diseases and supplies bio-lab reagents for R&D.
South Korea 086820
Biosynex Logo
European manufacturer of rapid diagnostic tests for professionals and consumer self-tests.
France ALBIO
Biotest AG Logo
Develops plasma protein products & biotherapeutics for immunology, haematology & intensive care.
Germany BIO3
Biotika A.S. Logo
Biotech firm making penicillin & polymyxin B APIs for human/vet use, plus contract manufacturing.
Slovakia BSL
Bioton S.A. Logo
Develops and manufactures recombinant human insulin for global diabetes care solutions.
Poland BIO
BIOVENTIX PLC Logo
Develops high-affinity sheep monoclonal antibodies for global clinical diagnostic immunoassays.
United Kingdom BVXP
Bioversys N Logo
Develops novel therapeutics to combat antimicrobial resistance in life-threatening infections.
Switzerland BIOV

Talk to a Data Expert

Have a question? We'll get back to you promptly.